Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$0.56 USD
-0.01 (-1.77%)
Updated Jul 5, 2024 03:59 PM ET
After-Market: $0.56 +0.01 (0.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Seelos Therapeutics, Inc. [SEEL]
Reports for Purchase
Showing records 1 - 20 ( 65 total )
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Acquires Clinical-Stage Sublingual Ketamine from iX Biopharma; $20M Raise
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
3Q21: Pivotal SLS-005 SCA3 Trial to Start, Encouraging Early Clinical Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Presents More Details from Part 1 of Potentially Pivotal SLS-002 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Getting Closer to SLS-002 Data and Increased Confidence; Rating to Buy/$8PT
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
2Q21: Still Not Sticking Our Necks Out for SLS-002
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
SLS-002 Delivers Seemingly Stellar Data, But We Need Controlled Results
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- Pscychedelic Literature Review
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare: Consumer Wellness -Psychedelics: An Emerging Market Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Enrollment of First 16 MDD Patients Means Interim Look Likely Early 2Q21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J